Westchester Capital Management (New York)’s Ginkgo Bioworks Holdings, Inc. Warrants, each whole warrant exercisable to purchase one-fortieth (1/40th) of a share of Class A Common Stock at an exercise price of $460.00 per share DNA.WS Stock Holding History

Westchester Capital Management (New York)’s Portfolio DNA.WS Stock Details DNA.WS Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2024 Q1	–	Sell	-20,000	Closed	-$2.1K	–	277
2023 Q4	$2.1K	Hold	20,000	–	–	﹤0.01%	259
2023 Q3	$4.5K	Hold	20,000	–	–	﹤0.01%	286
2023 Q2	$5.24K	Hold	20,000	–	–	﹤0.01%	298
2023 Q1	$3.6K	Hold	20,000	–	–	﹤0.01%	341
2022 Q4	$4K	Hold	20,000	–	–	﹤0.01%	415
2022 Q3	$15K	Hold	20,000	–	–	﹤0.01%	438
2022 Q2	$11K	Hold	20,000	–	–	﹤0.01%	410
2022 Q1	$17K	Hold	20,000	–	–	﹤0.01%	411
2021 Q4	$45K	Hold	20,000	–	–	﹤0.01%	372
2021 Q3	$68K	Buy	+20,000	New	+$71.2K	﹤0.01%	334

Other funds holding DNA.WS

LMR Partners London, United Kingdom $45.4B AUM 60.47% 1-Year Est. Return

Walleye Capital New York $28B AUM 44.22% 1-Year Est. Return

CAC

Cowen and Company New York $2.97B AUM 105.26% 1-Year Est. Return

Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return

JRCM

Jones Road Capital Management New York $55.3M AUM 29.97% 1-Year Est. Return

Altshuler Shaham Tel Aviv, Israel $5.54B AUM 44.68% 1-Year Est. Return

Guggenheim Capital Chicago, Illinois $12.9B AUM 27.3% 1-Year Est. Return

Walleye Trading New York $87.6B AUM 68.17% 1-Year Est. Return

Chescapmanager Baltimore, Maryland $1.12B AUM 67.49% 1-Year Est. Return

D.E. Shaw & Co New York $166B AUM 43.98% 1-Year Est. Return

Westchester Capital Management (New York)'s DNA.WS Position: Q1 2024 in Review

Westchester Capital Management (New York) sold out of Ginkgo Bioworks Holdings, Inc. Warrants, each whole warrant exercisable to purchase one-fortieth (1/40th) of a share of Class A Common Stock at an exercise price of $460.00 per share (DNA.WS) in Q1 2024, closing a stake of 20,000 shares — an estimated $2.1K sold.

Westchester Capital Management (New York) first reported a position in DNA.WS in Q3 2021 and held it in 10 quarters. The position peaked at $68K in Q3 2021. 28 funds tracked by Wall St. Rank hold DNA.WS as of Q1 2024.

Westchester Capital Management (New York) reported no remaining Ginkgo Bioworks Holdings, Inc. Warrants, each whole warrant exercisable to purchase one-fortieth (1/40th) of a share of Class A Common Stock at an exercise price of $460.00 per share position as of Q1 2024 after selling out during the quarter.
Westchester Capital Management (New York) sold 20,000 Ginkgo Bioworks Holdings, Inc. Warrants, each whole warrant exercisable to purchase one-fortieth (1/40th) of a share of Class A Common Stock at an exercise price of $460.00 per share shares in Q1 2024, an estimated $2.1K.
Westchester Capital Management (New York) first reported a position in Ginkgo Bioworks Holdings, Inc. Warrants, each whole warrant exercisable to purchase one-fortieth (1/40th) of a share of Class A Common Stock at an exercise price of $460.00 per share in Q3 2021 and held it in 10 quarters.
Westchester Capital Management (New York)'s Ginkgo Bioworks Holdings, Inc. Warrants, each whole warrant exercisable to purchase one-fortieth (1/40th) of a share of Class A Common Stock at an exercise price of $460.00 per share position peaked at $68K in Q3 2021.
28 funds tracked by Wall St. Rank held Ginkgo Bioworks Holdings, Inc. Warrants, each whole warrant exercisable to purchase one-fortieth (1/40th) of a share of Class A Common Stock at an exercise price of $460.00 per share as of Q1 2024.

Based on Westchester Capital Management (New York)'s 13F filing for Q1 2024, filed 15 May 2024.